Navigation Links
Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs

HELSINKI, Finland, July 5, 2012 /PRNewswire/ --

Oncos Therapeutics, the biotech company executing a clinical development program on its next generation oncolytic viruses, today announced the appointment of its Clinical Advisory Board (CAB). Bringing together a group of recognized leading experts in Oncology and Oncolytic Virus drug development, combining a wealth of clinical, strategic, and scientific experience in cancer drug development, immunotherapy, and oncolytic viruses, the CAB is well suited to support the company's innovative development strategy.

"Oncolytic viruses have the potential to become an important next-generation modality of cancer therapeutics" says Kapil Dhingra, consultant to the company and member of the Clinical Advisory Board.

"I am very pleased to be able to work together with this distinguished group of experts. They are already making a significant and very valuable contribution to our strategy as well as brainstorming novel approaches, and being very pragmatic and feasibility-oriented", says Dr. Mikael von Euler, CMO and Head of Research at Oncos who was recently appointed as Chairman of the Clinical Advisory Board.

Dr. von Euler is pleased to include the following leading oncology experts into the CAB: Dr. Kapil Dhingra, former Head of Roche Global Oncology Clinical Development; Dr. Lee Helman, Head of Molecular Oncology Section at the National Cancer Institute (NCI) and Co-founder of the Sarcoma Alliance for Research Through Collaboration (SARC)  in the USA; Dr. Kevin Harrington of the Institute of Cancer Research (ICR) and the Royal Marsden Hospital in London, one of the most experienced European investigators in oncolytic virus trials; Dr. Eva Galanis of Mayo Clinic, a leading scientist in oncolytic viruses in the USA; Dr. Luca Gianni, Director of Medical Oncology at the San Raffaele Hospital in Milan and the 2011 ASCO recipient of the Gianni Bonadonna Breast Cancer Award for his achievements in advancing the field of breast cancer research and Dr. Elke Jäger of the Nordwest Krankenhaus in Frankfurt, a distinguished cancer immunotherapy opinion leader in Europe.

"Our CAB has already made a significant contribution to our clinical development strategy", comments Pekka Simula, CEO and Co-Founder of Oncos Therapeutics. "It's a thrilling experience for the entire Oncosteam to be executing the strategic ideas of such talented oncology experts."

About Oncos Therapeutics

Oncos Therapeutics, based in Helsinki, Finland, develops novel cancer therapies based on its next generation oncolytic viruses. Its ongoing clinical development program of the lead virus CGTG-102 is based on clinical experience from an experimental treatment program with ten different oncolytic viruses, and is planned to expand into several countries in the near future. For more information about Oncos visit

SOURCE Oncos Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
2. OncoSec Medical Issues Letter to Shareholders
3. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
4. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
5. The New Generation of Antibody Therapeutics: Current Status and Future Prospects - Overview
6. Ovarian Cancer Therapeutics - Global Drug Forecasts and Treatment Analysis 2020
7. Lexicon Announces Publication of Results of Two Studies of LX4211 in Patients with Type 2 Diabetes in the Journal Clinical Pharmacology & Therapeutics
8. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
9. Faruqi & Faruqi, LLP is Investigating Pain Therapeutics Inc. on Behalf of its Shareholders (PTIE)
10. Sirnaomics Received NIH SBIR Grant for Developing Its Scarless Wound Healing siRNA Therapeutics
11. Frost & Sullivan: Launch of New Classes of Oral Antidiabetic Drugs by 2014 will Uplift Prospects for the European Diabetes Therapeutics Market
Post Your Comments:
(Date:11/25/2015)... 2015 ... the  "Global Drug Device Combination Products ... offering.  --> ) ... "Global Drug Device Combination Products Market ... --> Research and Markets ( ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... Nueva York , 24 de noviembre de ... del Avery Breathing Pacemaker System, se complace anunciar ... Ph.D. como consultor clínico. ... Foto -   ... Jonzon es un fisiólogo y consultor en neonatología ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. Seidel, DMD and ... of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced laser technology uses ... a dentist in Gettysburg, PA . From routine visits to cosmetic treatments, ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing ... of dental implants. , Missing teeth can lead to a variety of complications ...
(Date:11/24/2015)... Dallas, Texas (PRWEB) , ... November 24, 2015 , ... ... of all charitable donations are made in the last five weeks of the year ... #GivingTuesday was created in 2012 to connect the nation’s charities with those individuals who ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
(Date:11/24/2015)... ... November 24, 2015 , ... DMG Productions announced that they will feature ... quarter 2016 via Discovery Channel. Dates and show times TBA. , Aphria, Inc., is ... the business of producing and supplying medical marijuana pursuant to the Marijuana for Medical ...
Breaking Medicine News(10 mins):